Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 10

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 10
---
als and the other transactions contemplated by the Merger Agreement. Whether or not you expect to attend the NLS Meeting in person, please complete, date, sign and promptly return the accompanying proxy card in the enclosed postage paid envelope to ensure that your shares will be represented and voted at the NLS Meeting. More information about NLS, Kadimastem and the proposed transactions is contained in this proxy statement/prospectus. NLS urges you to read this proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER “RISK FACTORS” BEGINNING ON PAGE 25. NLS is excited about the opportunities the Merger brings to its shareholders, and thanks you for your consideration and continued support.

| Sincerely,                         |
| /s/ Ronald Hafner                  |
| Ronald Hafner                      |
| Chairman of the Board of Directors |

None of the Securities and Exchange Commission, Swiss Takeover Board, the Israel Securities Authority or any state securities commission has approved or disapproved the Merger described in this proxy statement/prospectus or the NLS Common Shares to be issued in connection with the Merger or passed upon the adequacy or accuracy of this proxy statement/prospectus. Any representation to the contrary is a criminal offense. This proxy statement/prospectus is not intended to be and is not a prospectus for purposes of the Israeli Securities Law, 5728-1968, and the Israeli Securities Authority has not approved this proxy statement/prospectus. The accompanying proxy statement is dated September 3, 2025, and is first being mailed to NLS shareholders on or about September 5, 2025.

PRELIMINARY PROXY STATEMENT, SUBJECT TO COMPLETION NLS PHARMACEUTICS LTD.
The Circle 6
8058 Zurich, Switzerland
Tel: +41.44.512.2150 NOTICE OF EXTRAORDINARY MEETING OF SHAREHOLDERS
TO BE HELD ON September 29, 2025 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, September 3, 2025 Postponement to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle6, 8058 Zurich, Switzerland (the “Company”), is pleased to invite you